Press release
Bullous Pemphigoid Market and Epidemiolohy 2032: Treatment Market, Drugs, Pipeline, FDA Approvals and Companies by DelveInsight | Akari Therapeutics, Immune Pharmaceuticals, iCo Therapeutics, Regeneron Pharmaceuticals, Sanofi, Nihon Pharmaceutical, Innate
Bullous Pemphigoid Market
Some of the vital points of the Bullous Pemphigoid Market Research Report
• Currently, there are no approved drugs for Bullous Pemphigoid in the United States. However, the PMDA approved Kenketu Glovenin-I in November 2015. The corticosteroid prednisolone was authorized in some EU countries for the Bullous Pemphigoid treatment.
• Prominent Bullous Pemphigoid companies such as Akari Therapeutics, Immune Pharmaceuticals, iCo Therapeutics, Regeneron Pharmaceuticals, Sanofi, Nihon Pharmaceutical, Innate Pharma, AstraZeneca, Alkahest, Inc., Grifols, and others are involved in developing Bullous Pemphigoid therapies. These companies hold the potential to create a significant positive shift in Bullous Pemphigoid market size.
• Bullous Pemphigoid pipeline possesses potential drugs in mid and late-stage developments to be approved shortly. Certain emerging Bullous Pemphigoid therapies such as Dupilumab, Nomacopan, Bertilimumab (iCo-008), Avdoralimab (IPH5401), Fasenra (benralizumab), AKST4290, and many others are in the clinical trials and have shown better efficacious results in Bullous Pemphigoid patients.
• With so many novel mechanisms of the emerging assets being tested for Bullous Pemphigoid, it is certainly sure that these therapies will boost the upcoming Bullous Pemphigoid market, focusing more on the severity-specific patient population.
• After the approval and the consecutive launch of late-phase drugs, the Bullous Pemphigoid market will face the toughest competition since there has not been any approval for the same in the US and EU. The recent approval of rituximab for Pemphigus Vulgaris treatment has revolutionized the management of this blistering autoimmune disease.
For further information on Bullous Pemphigoid Market Impact by Therapies, visit: https://www.delveinsight.com/report-store/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bullous Pemphigoid Overview:
Bullous Pemphigoid is an acquired autoimmune subepidermal bullous disease in which autoantibodies are directed against the skin's basement membrane zone components.
The first Bullous Pemphigoid symptom is usually redness and itching of the skin. Within weeks to months, thin-walled, tense blisters with clear fluid centers appear on the arms and legs, in the armpits, on the abdomen, and/or in the skin folds of the groin.
Bullous Pemphigoid typically affects the elderly but may rarely present in children and younger adults. According to DelveInsight's analysts, the total diagnosed Bullous Pemphigoid prevalent cases was 124,517 in the 7MM in 2020.
The Bullous Pemphigoid Market Report provides historical as well as forecasted epidemiological analysis segmented into:
• Bullous Pemphigoid Diagnosed Prevalent cases
• Gender-specific Bullous Pemphigoid Diagnosed Prevalent Cases
• Age-specific Bullous Pemphigoid Diagnosed Prevalent Cases
• Severity-specific Bullous Pemphigoid Diagnosed Prevalent Cases
Get a sample copy of this Bullous Pemphigoid market report: https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bullous Pemphigoid Treatment Market
The Bullous Pemphigoid therapeutic options are divided into anti-inflammatory drugs, immunosuppressive or immunomodulatory drugs, and procedures to remove circulating pathogenic antibodies or inflammatory mediators. The choice of treatment for Bullous Pemphigoid depends on the individual patient's circumstances, especially the severity and the presence of comorbidities.
Systemic Corticosteroids have been used and considered as the gold standard for Bullous Pemphigoid treatment for decades. The most commonly used drugs are prednisone and prednisolone that are considered to be bioequivalent. Topical or systemic corticosteroids are generally the first-line of treatment in Bullous Pemphigoid.
In patients who respond only partially to corticosteroid therapy or develop adverse effects, non-immunosuppressive agents such as tetracyclines, erythromycin, nicotinamide, and sulfone are used as adjuvant therapy, especially in patients with mild or moderate disease. Tetracycline and nicotinamide are also considered as Bullous Pemphigoid treatments in adults, in combination with topical corticosteroids.
Methotrexate (MTX) is another one of the first-line immunosuppressive treatment for Bullous Pemphigoid. It is a folic acid antagonist used at low doses as a corticosteroid-sparing agent in numerous diseases.
To date, only a few reported Bullous Pemphigoid cases have been treated with biologic agents, including the anti-CD20 agent rituximab and the TNFa antagonist etanercept. Intravenous immunoglobulin (IVIg) has been widely tried as an immunomodulatory agent in various autoantibody-mediated blistering diseases.
With so many novel mechanisms of the emerging assets being tested for Bullous Pemphigoid, it is certainly sure that these therapies will boost the upcoming Bullous Pemphigoid market, focusing more on the severity-specific patient population.
Bullous Pemphigoid Emerging Therapies Along with Key Players
• Dupilumab (Dupixent): Regeneron Pharmaceuticals/Sanofi
• Nomacopan (rVA576, Coversin): Akari Therapeutics
• iCo-008 (Bertilimumab): Immune Pharmaceuticals/iCo Therapeutics
• Avdoralimab (IPH5401): Innate Pharma
• Fasenra (benralizumab): AstraZeneca
• AKST4290: Alkahest, Inc./Grifols
And several others.
Request for Sample report @ https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bullous Pemphigoid Market Drivers
• Robust emerging pipeline - An increase in clinical trial activity for emerging therapies will boost the Bullous Pemphigoid market.
• The shortfall of approved therapies - Limited approved therapies in the market offers an excellent opportunity for the investment and development of novel therapies.
• Ubiquitous prevalence - The rise in the geriatric population and an increase in the risk factors such as neurological disorders, use of certain drugs, and others globally contribute to increased Bullous Pemphigoid prevalence.
• Patient compliance - Low-cost therapies and therapies with good patient compliance might be the game-changer for the Bullous Pemphigoid treatment market.
• Precise diagnostic procedures.
Request for a Webex demo of the Bullous Pemphigoid market report @ https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Bullous Pemphigoid Market Barriers
• Complications associated with available therapies - Available pharmacological therapies are often associated with severe complications.
• Delayed diagnosis - The lack of understanding of the pathophysiology and clinical relevance may represent a missed opportunity to make the correct diagnosis, leading to a delayed diagnosis.
• Polypharmacy - Polypharmacy is often associated with complications.
• Specific targeted therapies - Specific targeted therapies are lacking.
• Lack of disease awareness among clinicians - Poor knowledge of the disease among doctors leads to unsatisfactory current patient care and might hinder the growth of the Bullous Pemphigoid market and access to the medications.
• Strict pricing and reimbursement policies.
Scope of the Bullous Pemphigoid Market Insight Report
• Geography Covered: 7MM - The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan.
• Study Period: 3-year historical and 11-year forecasted analysis (2022-2032).
• Bullous Pemphigoid Markets Segmentation: By Geographies and By Bullous Pemphigoid Therapies (Historical and Forecasted, Current and Upcoming)
• Dominant Market Companies investigating its candidates for Bullous Pemphigoid: Akari Therapeutics, Immune Pharmaceuticals, iCo Therapeutics, Regeneron Pharmaceuticals, Sanofi, Nihon Pharmaceutical, Innate Pharma, AstraZeneca, Alkahest, Inc., Grifols, and several others.
• Analysis: Comparative and conjoint analysis of emerging therapies.
• Case Studies
• KOL's Views
• Analyst's View
Request for Sample report @ https://www.delveinsight.com/sample-request/bullous-pemphigoid-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Contents
1. Key Insights
2. Bullous Pemphigoid Report Introduction
3. Bullous Pemphigoid Market Overview at a Glance
4. Executive Summary of Bullous Pemphigoid
5. Disease Overview of Bullous Pemphigoid
6. Bullous Pemphigoid Epidemiology and Patient Population
7. Bullous Pemphigoid Patient Journey
8. Bullous Pemphigoid Marketed Therapies
8.1. Kenketu Glovenin-I (NPB-01): Nihon Pharmaceutical
9. Bullous Pemphigoid Emerging Drugs
9.1. Key Cross Competition
9.2. Dupilumab (Dupixent): Regeneron Pharmaceuticals/Sanofi
9.3. Nomacopan (rVA576, Coversin): Akari Therapeutics
9.4. iCo-008 (Bertilimumab): Immune Pharmaceuticals/iCo Therapeutics
9.5. Avdoralimab (IPH5401): Innate Pharma
9.6. Fasenra (benralizumab): AstraZeneca
9.7. AKST4290: Alkahest, Inc./Grifols
10. 7MM Bullous Pemphigoid Market Analysis
11. KOL Views
12. Bullous Pemphigoid Market Drivers
13. Bullous Pemphigoid Market Barriers
14. SWOT Analysis of Bullous Pemphigoid
15. Bullous Pemphigoid Unmet Needs
16. Appendix
17. DelveInsight Capabilities
18. Disclaimer
Trending Reports:
• Gastric neuroendocrine tumours market: https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
• Bronchial spasms market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Wilms tumor market: https://www.delveinsight.com/report-store/wilms-tumor-market
• Interbody cages market: https://www.delveinsight.com/report-store/interbody-cages-market
• Prefilled syringes market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Duchenne muscular dystrophy market: https://www.delveinsight.com/infographics/duchenne-muscular-dystrophy-market
• Cardiac amyloidosis market: https://www.delveinsight.com/report-store/hereditary-amyloidosis-market
• Encephalitis market: https://www.delveinsight.com/report-store/encephalitis-market
• Age-related macular degeneration market: https://www.delveinsight.com/infographics/wet-age-related-macular-degeneration-wet-amd-market
• Polycythemia market: https://www.delveinsight.com/report-store/polycythemia-vera-market
• Myelofibrosis market: https://www.delveinsight.com/report-store/myelofibrosis-market
• Urolithiasis market: https://www.delveinsight.com/report-store/urolithiasis-management-devices-market
• Acute coronary syndrome market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-pipeline-insight
• Lymphocytopenia market: https://www.delveinsight.com/report-store/idiopathic-cd4-lymphocytopenia-market
• Minimal residual disease market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Pharma licensing services: https://www.delveinsight.com/consulting/licensing-services
• Biotech consulting: https://www.delveinsight.com/consulting
• Biliary atresia market: https://www.delveinsight.com/report-store/biliary-atresia-market
• Surgical site infection ssi market: https://www.delveinsight.com/report-store/surgical-site-infections-ssi-market
• Thyroid eye disease market: https://www.delveinsight.com/report-store/thyroid-eye-disease-market
• Chronic inflammatory demyelinating polyneuropathy market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market-insight-epidemiology-and-market-forecast
• Chronic inflammtory demyelinating polyneuropathy market: https://www.delveinsight.com/report-store/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market-insight-epidemiology-and-market-forecast
• Biochips market: https://www.delveinsight.com/blog/biochips-in-the-healthcare-industry
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About Delveinsight:
DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.
Get hold of all the Pharma and healthcare market research reports on our market research subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Bullous Pemphigoid Market and Epidemiolohy 2032: Treatment Market, Drugs, Pipeline, FDA Approvals and Companies by DelveInsight | Akari Therapeutics, Immune Pharmaceuticals, iCo Therapeutics, Regeneron Pharmaceuticals, Sanofi, Nihon Pharmaceutical, Innate here
News-ID: 3059528 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Bullous
Bullous Keratopathy Market is expected to reach USD 755 million by 2034
Bullous keratopathy is a progressive corneal disorder characterized by corneal endothelial cell dysfunction, leading to corneal edema, blister-like formations, and painful vision loss. It is most commonly associated with aging, cataract surgery complications, and conditions such as Fuchs' endothelial dystrophy. Left untreated, bullous keratopathy can cause severe visual impairment, making it a significant cause of corneal blindness worldwide.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72223
As the global burden…
Bullous Pemphigoid Market to Set Phenomenal Growth From 2025 to 2034
Introduction
Bullous pemphigoid (BP) is a rare, chronic, autoimmune blistering skin disorder that primarily affects the elderly population. Characterized by large, fluid-filled blisters, intense itching, and significant discomfort, BP is associated with immune system dysfunction, where antibodies attack proteins in the skin.
Although rare, its prevalence is rising due to aging populations, improved diagnostic accuracy, and increasing autoimmune disease incidence worldwide.
The global bullous pemphigoid market is gaining momentum as awareness grows…
Bullous Pemphigoid Market Projected to Witness Innovation in Autoimmune Therapie …
Bullous Pemphigoid Market Snapshot
The Bullous Pemphigoid Market is projected to grow at a CAGR of 5.8% during the forecast period 2025-2032.
Coherent Market Insights proudly presents its latest Bullous Pemphigoid Market Research Report, delivering a detailed examination of the U.S. Bullous Pemphigoid Market outlook from 2025 to 2032. This comprehensive analysis provides strategic forecasts at both national and regional levels, addressing evolving supply networks, payer-provider collaboration, and competitive strategies. As the…
Bullous Pemphigoid Treatment Market Size, Share, Analysis Report and Forecast 20 …
According to the report by Expert Market Research (EMR), the global bullous pemphigoid treatment market is being driven by the rising skin disease treatment market. Aided by rising skin disease treatment market and rising accessibility of healthcare facilities, the skin disease treatment market is expected to grow at a CAGR of 3% in the forecast period of 2024-2032.
Bullous pemphigoid is a chronic autoimmune skin disorder characterised by large, tense blisters…
Bullous Keratopathy Treatment Market Size, Share, Industry, Forecast and Outlook …
Bullous Keratopathy Treatment Market Overview
The global Bullous Keratopathy Treatment Market is anticipated to achieve a high Compound Annual Growth Rate (CAGR) during the forecast period from 2023 to 2030.
Bullous Keratopathy
Bullous keratopathy, also known as corneal edema, is characterized by the swelling of the cornea due to the failure of the corneal endothelium to maintain its transparent and dehydrated state. This condition often results from corneal endothelial dystrophy or trauma. The…
Bullous Pemphigoid Market 2020 Enhancement in Medical Sector
Bullous Pemphigoid - Pipeline Insight, 2020
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Bullous Pemphigoid Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This…
